Forward Price-to-Revenue Multiple: Imunon (IMNN)
Imunon, Inc. (IMNN) develops DNA vaccines to combat oncology, leveraging the success of medical trials. The absence of current sales makes the stock price dependent on research, which is illustrated by the forward P/S based on forecasts on the general GURU.Markets platform chart, where the value of 127.20 characterizes this level. The strategy is based on the TheraPlas system for patients with severe forms of tumors.
imunon.com - analytical breakdowns and key metrics (IMNN)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- company liabilities and liquidity data:
- financial results and valuation multiples details:
IMNN - Net Profit|Projected Future Earnings Imunon, Inc.|IMNN - Business Payback Period|Future Price to Earnings Imunon|IMNN - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio IMNN|IMNN - Operating profit EBITDA|Earnings per share for the last twelve months Imunon|IMNN - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months imunon.com|IMNN - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Imunon, Inc.
- sales volume and revenue indicators:
Fundamental company valuation:Celsion Corporation IMNN
Conservative capital requires transparent forecasting of business sustainability, which is why this indicator compares current market capitalization with expected sales volume to assess the company's margin of safety. The forward P/S dynamics for Imunon, Inc. (IMNN) reflect market expectations regarding the commercialization of DNA plasmid therapy for ovarian cancer, allowing investors to evaluate the extent to which R&D risks are currently priced into the stock.
Competitor analysis for Imunon, Inc.
Forward P/S Multiple TEM (Tempus AI, Inc.)|QGEN - Forward Price-to-Revenue Multiple|IONS: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Repligen Inc. RGEN|RNA: Forward P/S Multiple|CRSP - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio GeneDx|Forward Price-to-Revenue Multiple Ultragenyx Pharmaceutical Inc. (RARE)|Price-to-Projected Revenue Ratio Beam Therapeutics Corp (BEAM)|Sarepta Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Twist Bioscience TWST|TXG: Market Cap to Projected Revenue|Intellia Therapeutics, Inc. - Forward P/S Multiple|STOK (Stoke Therapeutics Inc) - Market Cap to Projected Revenue|BioLife Corp (BLFS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue WVE|MAZE (Maze Therapeutics Inc) - Forward P/S Multiple|Forward P/S Multiple sionnatx.com|Forward P/S Multiple PRME|Market Cap to Expected Sales Ratio Taysha Gene Therapies Inc|Price-to-Projected Revenue Ratio uniQure Corp QURE|MGTX - Forward Price-to-Revenue Multiple|RGNX: Forward Price-to-Revenue Multiple|SLDB - Forward P/S Multiple|Ocugen (OCGN) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue PACB|Price-to-Projected Revenue Ratio Benitec|Market Cap to Future Revenue Ratio Design Corp DSGN|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Market Cap to Projected Revenue|Lexeo Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales KRRO|Editas - Forward P/S Multiple|Market Cap to Expected Sales Ratio Silence Therapeutics Corp SLN|proqr.com (PRQR) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CDXS|SGMO (Sangamo Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Nautilus Biotechnology Inc (NAUT)|Forward Price-to-Revenue Multiple MGX (Metagenomi, Inc)|Market Cap to Expected Sales Ratio Precision BioSciences Inc.|Forward P/S Multiple GBIO (Generation Bio)|Market Cap to Expected Sales Ratio boundlessbio.com (BOLD)|XCUR - Price-to-Projected Revenue Ratio|Phio Pharmaceuticals (PHIO) - Forward Price-to-Revenue Multiple|mustangbio.com (MBIO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue RNAZ|Price-to-Projected Revenue Ratio Bionano Genomics Inc.|Market Cap to Projected Revenue APDN (adnas.com)|Forward P/S Multiple BLUE|immunoprecise.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega OMGA|OMIC: Market Cap to Projected Revenue|Regulus Therapeutics - Forward P/S Multiple|SYRS - Forward P/S Multiple|TBIO: Forward P/S Multiple|TCON - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Unity Bio
